Enveric net loss narrows to $3 million in Q2 FY26; loss per share improves to $0.76PUBT·Aug 14 at 03:06 PMENVB-1.37%
Enveric Biosciences Says New Preclinical Data Confirms Non-Hallucinogenic Profile For Lead Psychiatric Candidatebenzinga_article·Aug 5 at 08:30 AMENVB-1.37%
Enveric Biosciences says preclinical GloSensor assay supports non-hallucinogenic profile for EB-003PUBT·Aug 5 at 07:00 AMENVB-1.37%
Enveric Biosciences CEO joins B. Riley Securities neuropsychiatry fireside chat at Mind, Muscle & Vision SummitPUBT·Jun 29 at 07:01 AMENVB-1.37%RILY-0.83%
Enveric Biosciences Announces Participation in 2026 BIO International Convention | ENVB Stock NewsStockTitan·Jun 16 at 12:28 AMENVB-1.37%
Enveric Biosciences shares are trading lower. The company announced preclinical in vitro results showing no photoreactive potential for EB‑003, further derisking its neuropsychiatric program.benzinga_article·May 19 at 12:34 PMENVB-1.37%XBI-0.51%
